DiaMedica Therapeutics Inc. (NASDAQ:DMAC – Get Rating) Director Randall Michael Giuffre acquired 65,000 shares of DiaMedica Therapeutics stock in a transaction that occurred on Friday, June 23rd. The shares were bought at an average price of $3.91 per share, with a total value of $254,150.00. Following the transaction, the director now directly owns 360,355 shares […]
Related Keywords
Randall Michael Giuffre , Diamedica Therapeutics Company Profile , Renaissance Technologies , Dimensional Fund Advisors , Nasdaq , Catalyst Financial Partners , Diamedica Therapeutics Inc , Citadel Advisors , Diamedica Therapeutics , Get Rating , Director Randall Michael Giuffre , Medica Therapeutics , Street Group , Financial Partners , Fund Advisors , Medica Therapeutics Inc , Diamedica Therapeutics Daily , Nasdaq Dmac , Sdmac , Medical , Insider Trading , Nsider Trades , Stocks ,
vimarsana.com © 2020. All Rights Reserved.